Certified by Founder
Lodge
AlgoTx
start up
France
- Suresnes, Ile-de-France
- 15/03/2023
- Series B
- $21,157,000
AlgoTx develops novel solutions for complex pain. Our lead program, ATX01, targets highly prevalent Chemotherapy-Induced Peripheral Neuropathy and the orphan disease erythromelalgia.
- Industry Biotechnology Research
- Website https://www.linkedin.com/company/algotx/about/
- LinkedIn https://www.linkedin.com/company/algotx/
FYLD | $41,000,000 | (Feb 18, 2026)
The Compression Company | $3,400,000 | (Feb 18, 2026)
Helia Care, Inc. | $3,000,000 | (Feb 18, 2026)
Dataro | $14,280,000 | (Feb 18, 2026)
Daffodil Health Corp | $16,300,000 | (Feb 18, 2026)
Sphinx(US) | $7,100,000 | (Feb 18, 2026)
Autosana (YC S25) | $3,200,000 | (Feb 18, 2026)
Tangible | $4,300,000 | (Feb 18, 2026)
Certivo | $4,000,000 | (Feb 18, 2026)
GelMEDIX | $13,000,000 | (Feb 18, 2026)
QuadSci.ai | $8,000,000 | (Feb 18, 2026)
Breaker | $6,000,000 | (Feb 18, 2026)
Bland Company | $2,670,000 | (Feb 18, 2026)